[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623853":3},{"organization":4,"outcomesModule":7,"designInfo":58,"detailedDescription":59,"studyPopulation":62,"armGroups":59,"interventions":63,"overallOfficials":68,"centralContacts":72,"locations":83,"responsibleParty":107,"collaborators":59,"id":109,"slug":59,"hasResults":110,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":59,"eligibilityCriteria":114,"healthyVolunteers":110,"sex":115,"minAge":116,"maxAge":117,"enrollmentInfo":118,"targetDuration":59,"studyType":121,"phases":59,"briefSummary":122,"conditions":123,"keywords":59,"overallStatus":86,"whyStopped":59,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":134},{"fullName":5,"class":6},"Université Catholique de Louvain","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":47},[9],{"measure":10,"description":11,"timeFrame":12},"Correlation between weight loss after treatment and clinical, neuropsychological and biological parameters.","The percentage of excessive weight loss after treatment will be correlated with\n\n* Clinical parameters (Binge Eating Scale and modified Yale Food Addiction Scale 2.0)\n* Neuropsychological parameter (Barratt Impulsivness Scale and Trail Making Test)\n* Biological parameters","Throughout the entire study, aproximately during 5 years",[14,17,20,23,26,29,32,35,38,41,44],{"measure":15,"description":16,"timeFrame":12},"Binge Eating Disorder.","Evaluation of eating disorders using the Binge Eating Scale (BES).",{"measure":18,"description":19,"timeFrame":12},"Food Addiction.","Evaluation of food addiction will be performed using modified Yale Food Addiction Scale 2.0.",{"measure":21,"description":22,"timeFrame":12},"Eating attitudes","Eating patterns and habits will be screened using the Eating Attitude Test 26",{"measure":24,"description":25,"timeFrame":12},"Cognitive flexibility.","Neuropsychological evaluation of cognitive flexibility will be performed with the Trail Making Test",{"measure":27,"description":28,"timeFrame":12},"Impulsivity.","Impulsivity will be assessed using the Barrat Impulsiveness Scale (BIS)",{"measure":30,"description":31,"timeFrame":12},"Self-reported quality of life.","Self-reported quality of life will be assessed using the QOLOD (Quality of Life, Obesity and Dietetics)",{"measure":33,"description":34,"timeFrame":12},"Obesity.","Weight will be measured at each timepoint",{"measure":36,"description":37,"timeFrame":12},"Physical activity.","Weekly physical activity will be reported with the Godin Leisure Time Exercise Questionnaire (GLTEQ)",{"measure":39,"description":40,"timeFrame":12},"Food intake.","Eating habits will be recorded with a Food Frequency Questionnaire (FFQ)",{"measure":42,"description":43,"timeFrame":12},"Blood samples","Blood samples will be collected and processed for metabolomic analyses.",{"measure":45,"description":46,"timeFrame":12},"Fecal sample","Feces samples will be collected and processed to evaluation gut-microbiota composition",[48,52,55],{"measure":49,"description":50,"timeFrame":51},"Sociodemographic data","Number of children and marital status will be recorded","Once at inclusion",{"measure":53,"description":54,"timeFrame":51},"Medical history","Information concerning medical comorbidities will be collected from the patient medical record.",{"measure":56,"description":57,"timeFrame":51},"Childhood Trauma.","Assessment of adverse life events and trauma will used the Childhood Trauma Questionnaire - short form.",{"allocation":59,"interventionModel":59,"interventionModelDescription":59,"primaryPurpose":59,"observationalModel":60,"timePerspective":61,"maskingInfo":59},null,"COHORT","PROSPECTIVE","Participants initiating an anti-obesity medication or candidates for bariatric surgery once its indication has been validated by a multidisciplinary committee, following medical, nutritional and psychological evaluations.",[64],{"type":65,"name":66,"description":67,"armGroupLabels":59,"otherNames":59},"PROCEDURE","Pharmacological or surgical treament of obesity","Longitudinal follow-up of participants who initiate an anti-obesity medication or whose application for bariatric surgery was accepted. It will combine anthropometric, clinical, neuropsychological and biological measurements taken at various timepoints. Participants will be asked to complete a set of online questionnaires and data will be recorded anonymously. Biological samples will be collected at various time points.",[69],{"name":70,"affiliation":5,"role":71},"Amandine Everard, Professor","STUDY_DIRECTOR",[73,79],{"name":74,"role":75,"phone":76,"phoneExt":77,"email":78},"Pr Amandine Everard, Professor","CONTACT","+ 32 (0)2 436 22 10","+32","amandine.everard@uclouvain.be",{"name":80,"role":75,"phone":81,"phoneExt":77,"email":82},"Yannick Deswysen, Doctor","+ 32 2 764 22 13","yannick.deswysen@saintluc.uclouvain.be",[84],{"facility":85,"status":86,"city":87,"state":88,"zip":89,"country":90,"countryCode":91,"cosmosGeoPoint":92,"geoPoint":97,"contacts":98},"Cliniques Universitaires Saint-Luc","RECRUITING","Brussels","Brussels Capital","1200","Belgium","BE",{"type":93,"coordinates":94},"Point",[95,96],4.34878,50.85045,{"lat":96,"lon":95},[99,102,104],{"name":100,"role":75,"phone":101,"phoneExt":59,"email":82},"Dr Yannick Deswysen, Doctor","+32 (0) 2 764 22 13",{"name":80,"role":103,"phone":59,"phoneExt":59,"email":59},"PRINCIPAL_INVESTIGATOR",{"name":105,"role":106,"phone":59,"phoneExt":59,"email":59},"Audrey Loumaye, Professor","SUB_INVESTIGATOR",{"type":108,"investigatorFullName":59,"investigatorTitle":59,"investigatorAffiliation":59,"oldNameTitle":59,"oldOrganization":59},"SPONSOR","100623853",false,"NCT07402031","Predicting Weight Loss After Pharmacological or Surgical Treatment in Patients With Obesity","Research of Predictive Factors of Weight Loss After Pharmacological or Surgical Treatment in Patients Suffering From Obesity","Inclusion criteria:\n\n* Age between 18 and 65 years\n* Obesity, with bariatric surgery indicated after a multidisciplinary evaluation in case of surgical treatment.\n* Good physical and mental health, enabling informed consent.\n* French speaker\n\nExclusion criteria:\n\n* Legal protection\n* Pregnancy or breastfeeding\n* History of bariatric surgery (except gastric banding, provided it was removed more than five years ago).\n* Acute or progressive chronic disease\n* Alcohol consumption of more than 20 g\u002Fday\n* Inflammatory bowel disease;\n* Digestive autonomic diabetic neuropathy.\n* Consumption of dietary supplements (stanols, probiotics, prebiotics or omega-3).\n* Following a vegan or gluten-free diet or being lactose intolerant.\n* Fibre consumption \\>30 g\u002Fday\n* Recent change in antidiabetic medication within the past 3 months.","ALL","18 Years","65 Years",{"count":119,"type":120},100,"ESTIMATED","OBSERVATIONAL","As with other nutritional strategies, the clinical response to bariatric surgery can be highly variable, with weight regain being a frequent occurrence. Recent evidence on anti-obesity medication indicate similar inter-individual variability in clinical response. Among multiples factors, co-occurrence of eating disorders such as binge eating disorder has been implicated in insufficient clinical response. Improving our ability to predict how patients will respond to obesity treatment is necessary in order to tailor the care pathways we offer. The mechanisms involved in disturbances of eating behaviour before and after surgery remain largely unknown. This study aims to identify the predictive factors of weight loss after pharmacological or surgical treatment, as well as the cognitive and biological mechanisms that mediate this effect.",[124],"Obesity & Overweight","2026-05-11",{"date":127,"type":128},"2026-05-14","ACTUAL",{"date":130,"type":128},"2026-05-05",{"date":132,"type":120},"2036-01",{"name":5,"class":6},1]